Cargando…

Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report

Ossifying fibromyxoid tumor of soft parts (OFMT) is a rare mesenchymal neoplasm of uncertain lineage. OMFT normally has a benign clinical course, and malignant variants are considered unusual. Criteria defining malignancy have not yet been clearly identified and universally accepted, and there is di...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster-Davies, Harri, Jessop, Zita M., Clancy, Rachel M., Vijayasurej, Kerrin, Vass, Johanne, Bragg, Thomas, Brotto, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994011/
https://www.ncbi.nlm.nih.gov/pubmed/33786264
http://dx.doi.org/10.1097/GOX.0000000000003482
_version_ 1783669675487395840
author Foster-Davies, Harri
Jessop, Zita M.
Clancy, Rachel M.
Vijayasurej, Kerrin
Vass, Johanne
Bragg, Thomas
Brotto, Maurizio
author_facet Foster-Davies, Harri
Jessop, Zita M.
Clancy, Rachel M.
Vijayasurej, Kerrin
Vass, Johanne
Bragg, Thomas
Brotto, Maurizio
author_sort Foster-Davies, Harri
collection PubMed
description Ossifying fibromyxoid tumor of soft parts (OFMT) is a rare mesenchymal neoplasm of uncertain lineage. OMFT normally has a benign clinical course, and malignant variants are considered unusual. Criteria defining malignancy have not yet been clearly identified and universally accepted, and there is diagnostic uncertainty between pathologists as to how best to recognize a malignant variant. We present the case of a 68-year-old male patient who, following initial diagnosis of typical OFMT in the left scapular region, presented to the sarcoma service 9 years later with a short history of a solid lesion in the right calf. Biopsy confirmed metastatic OFMT and further imaging identified three other radiologically similar but distant lesions, which were later resected. The histology of the initial biopsy was reviewed, and the original observations were found to be accurate and due to current diagnostic criteria, the specimen was reported as typical. We propose that this case report contributes to a growing body of literature suggesting that negative S100 expression may be a useful feature in identifying and characterizing malignant OFMT.
format Online
Article
Text
id pubmed-7994011
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-79940112021-03-29 Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report Foster-Davies, Harri Jessop, Zita M. Clancy, Rachel M. Vijayasurej, Kerrin Vass, Johanne Bragg, Thomas Brotto, Maurizio Plast Reconstr Surg Glob Open Experimental Ossifying fibromyxoid tumor of soft parts (OFMT) is a rare mesenchymal neoplasm of uncertain lineage. OMFT normally has a benign clinical course, and malignant variants are considered unusual. Criteria defining malignancy have not yet been clearly identified and universally accepted, and there is diagnostic uncertainty between pathologists as to how best to recognize a malignant variant. We present the case of a 68-year-old male patient who, following initial diagnosis of typical OFMT in the left scapular region, presented to the sarcoma service 9 years later with a short history of a solid lesion in the right calf. Biopsy confirmed metastatic OFMT and further imaging identified three other radiologically similar but distant lesions, which were later resected. The histology of the initial biopsy was reviewed, and the original observations were found to be accurate and due to current diagnostic criteria, the specimen was reported as typical. We propose that this case report contributes to a growing body of literature suggesting that negative S100 expression may be a useful feature in identifying and characterizing malignant OFMT. Lippincott Williams & Wilkins 2021-03-23 /pmc/articles/PMC7994011/ /pubmed/33786264 http://dx.doi.org/10.1097/GOX.0000000000003482 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Experimental
Foster-Davies, Harri
Jessop, Zita M.
Clancy, Rachel M.
Vijayasurej, Kerrin
Vass, Johanne
Bragg, Thomas
Brotto, Maurizio
Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title_full Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title_fullStr Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title_full_unstemmed Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title_short Reduced S100 Protein Expression in Malignant Ossifying Fibromyxoid Tumors: A Case Report
title_sort reduced s100 protein expression in malignant ossifying fibromyxoid tumors: a case report
topic Experimental
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994011/
https://www.ncbi.nlm.nih.gov/pubmed/33786264
http://dx.doi.org/10.1097/GOX.0000000000003482
work_keys_str_mv AT fosterdaviesharri reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT jessopzitam reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT clancyrachelm reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT vijayasurejkerrin reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT vassjohanne reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT braggthomas reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport
AT brottomaurizio reduceds100proteinexpressioninmalignantossifyingfibromyxoidtumorsacasereport